Skip to main content

Advertisement

Table 5 Most important treatment goals

From: Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

   Symptom Quartile Prognostic Risk
Treatment Goal,a n (%) All Respondents Q4 Q1 High Low
MF n = 207 n = 73 n = 43 n = 63 n = 9
 Slow/delay progression of condition 86 (42) 27 (37) 18 (42) 28 (44) 6 (67)
 Better QoL 43 (21) 26 (36) 2 (5) 16 (25) 0
 Healthy blood counts 23 (11) 6 (8) 10 (23) 5 (8) 1 (11)
 Symptom improvement 14 (7) 5 (7) 1 (2) 1 (2) 1 (11)
 Reduction in spleen size 13 (6) 2 (3) 5 (12) 3 (5) 0
 Reduce blood transfusions 12 (6) 4 (6) 2 (5) 6 (10) 0
PV n = 380 n = 98 n = 88 n = 101 n = 26
 Slow/delay progression of condition 96 (25) 23 (24) 21 (24) 20 (20) 7 (27)
 Prevention of vascular/thrombotic events 92 (24) 17 (17) 16 (18) 25 (25) 5 (19)
 Healthy blood counts 68 (18) 10 (10) 27 (31) 22 (22) 3 (12)
 Better QoL 45 (12) 19 (19) 5 (6) 11 (11) 4 (15)
 Symptom improvement 33 (9) 21 (21) 1 (1) 6 (6) 2 (8)
 Hematocrit levels <45 % 22 (6) 4 (4) 9 (10) 9 (9) 1 (4)
ET n = 226 n = 42 n = 71 n = 35 n = 46
 Prevention of vascular/thrombotic events 78 (35) 9 (21) 28 (39) 12 (34) 15 (33)
 Slow/delay progression of condition 48 (21) 8 (19) 16 (23) 5 (14) 14 (30)
 Healthy blood counts 39 (17) 5 (12) 18 (25) 5 (14) 4 (9)
 Better QoL 31 (14) 14 (33) 2 (3) 3 (9) 9 (20)
 Symptom improvement 21 (9) 3 (7) 3 (4) 6 (17) 2 (4)
  1. ET = essential thrombocythemia; MF = myelofibrosis; PV = polycythemia vera; QoL = quality of life
  2. aMost important treatment goal, other than a cure, reported by ≥5 % of respondents in each MPN group